...
首页> 外文期刊>EFSA Journal >Scientific Opinion on the substantiation of a health claim related Immunofortis? and strengthening of the baby's immune system pursuant to Article 14 of Regulation (EC) No 1924/2006
【24h】

Scientific Opinion on the substantiation of a health claim related Immunofortis? and strengthening of the baby's immune system pursuant to Article 14 of Regulation (EC) No 1924/2006

机译:关于证实与免疫增强有关的健康要求的科学意见?和根据(EC)1924/2006号法规第14条,加强婴儿的免疫系统

获取原文

摘要

Following an application from Danone Baby Nutrition, submitted pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of The Netherlands, the Panel on Dietetic Products, Nutrition and Allergies was asked to deliver an opinion on the scientific substantiation of a health claim related to Immunofortis? to naturally strengthen the baby's immune system. The scope of the application was proposed to fall under a health claim referring to children's development and health The Panel considered that the food constituent, Immunofortis?, a 9:1 mixture of short‐chain galacto‐and long‐chain fructo‐oligosaccharides, was sufficiently characterised. The target population consisted of infants who were not breastfed or who were partially breastfed and who were less than 12 months old. The Panel considered that a well‐functioning immune system includes the initiation of appropriate adaptive immune responses and an appropriate defence against pathogens and was a beneficial physiological effect.In weighing the evidence, the Panel took into account that the one human intervention study investigating the effects of Immunofortis? on the incidence of atopic dermatitis and the overall cumulative incidence of infections had considerable limitations, that the evidence for an effect of Immunofortis? on the reduction of potentially pathogenic bacteria was inconsistent, that the evidence for an effect of Immunofortis? on immune function animal studies did not predict the occurrence of an effect in humans, and that the evidence presented in support of a biologically plausible mechanism by which Immunofortis? could exert the claimed effect was not convincing.The Panel concluded that the evidence provided was insufficient to establish a cause and effect relationship between the consumption of Immunofortis? and the claimed effect of initiation of appropriate immune responses including the defence against pathogens.
机译:达能婴儿营养公司根据(EC)第1924/2006号法规第14条通过荷兰主管当局提出申请后,要求营养产品,营养和过敏问题专门委员会就以下方面的科学依据发表意见:是否有与免疫增强有关的健康声明?自然增强宝宝的免疫系统。提议将适用范围归入关于儿童发育与健康的健康要求范围内。小组认为,食品成分Immunofortis?是短链半乳糖和长链低聚果糖的9:1混合物,充分表征。目标人群包括未母乳喂养或部分母乳喂养且年龄小于12个月的婴儿。专家组认为,运转良好的免疫系统包括适当的适应性免疫反应的启动和对病原体的适当防御,是有益的生理效应。在权衡证据时,专家组考虑了一项旨在研究这种效应的人为干预研究Immunofortis?对特应性皮炎的发生和感染的总体累积发生率有相当大的局限性,那是否证明免疫增强作用有效?关于减少潜在致病菌的说法不一致,是否证明了免疫增强作用?免疫功能的动物研究未能预测人类是否会发生这种作用,并且所提供的证据支持免疫增强作用的生物学上合理的机制吗?小组得出结论认为,所提供的证据不足以建立免疫强化的消费之间的因果关系吗?以及要求的引发适当的免疫反应(包括防御病原体)的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号